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Introduction
The heart is composed of multiple cell types, including cardio­
myocytes (CMs), endothelial cells (ECs), and smooth muscle cells 
(SMCs; Martin­Puig et al., 2008). The mammalian heart is divided 
in four chambers: two atria and two ventricles, which are con­
nected to the pulmonary and the general circulation by four vessels 
(Olson, 2006). During embryonic development, the heart is formed 
by two sources of multipotent cardiovascular progenitors (MCPs), 
with an additional contribution of neural crest cells (Buckingham 
and Desplan, 2010). The first heart field (FHF) MCPs, which form 
the cardiac crescent around embryonic day 7 during mouse devel­
opment, give rise to the cells of both atria and to all CMs of the left 
ventricle. The second heart field (SHF) MCPs, which derive from 
the pharyngeal mesoderm, give rise to the cells of the right   
ventricle, some cells in both atria, as well as cells that form the 
outflow tract. Random labeling of cardiac precursors during em­
bryonic development also revealed the existence of rare clones that 
contributed to both FHF and SHF lineages and that could repre­
sent a common cardiovascular progenitor for both heart fields 
(Meilhac et al., 2004). Recent studies showed that, during mouse 
embryonic development, tripotent MCPs that are able to differen­
tiate at the clonal level into CMs, SMCs, and ECs can be marked 
and isolated based on Brachyury (Bry) and Flk1 (Kattman et al., 
2006) or Isl1 and Flk1 expression (Moretti et al., 2006), whereas 
bipotent MCPs that give rise to CM and SMC lineages can be iso­
lated based on Nkx2-5 and c­Kit expression (Wu et al., 2006). 
These studies demonstrated that cardiac cells arise from the differ­
entiation of multipotent progenitors, with the ability to differenti­
ate at the clonal level into the different cardiovascular lineages 
(Kattman et al., 2006; Moretti et al., 2006; Wu et al., 2006).
D
uring  embryonic  development  and  embryonic 
stem cell (ESC) differentiation, the different cell 
lineages of the mature heart arise from two types 
of  multipotent  cardiovascular  progenitors  (MCPs),  the 
first and second heart fields. A key question is whether 
these two MCP populations arise from differentiation of 
a  common  progenitor.  In  this  paper,  we  engineered 
Mesp1–green fluorescent protein (GFP) ESCs to isolate 
early MCPs during ESC differentiation. Mesp1-GFP cells 
are strongly enriched for MCPs, presenting the ability to 
differentiate into multiple cardiovascular lineages from 
both heart fields in vitro and in vivo. Transcriptional pro-
filing of Mesp1-GFP cells uncovered cell surface mark-
ers  expressed  by  MCPs  allowing  their  prospective 
isolation. Mesp1 is required for MCP specification and 
the expression of key cardiovascular transcription fac-
tors. Isl1 is expressed in a subset of early Mesp1-expressing 
cells  independently  of  Mesp1  and  acts  together  with 
Mesp1 to promote cardiovascular differentiation. Our 
study identifies the early MCPs residing at the top of   
the cellular hierarchy of cardiovascular lineages during 
ESC differentiation.
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these early Mesp1­expressing cells are enriched for MCPs of 
both heart fields, which give rise upon differentiation to all 
cardiovascular cell lineages both in vitro and in vivo. By tran­
scriptionally profiling the early Mesp1­expressing cells, we un­
covered cell surface markers allowing their prospective isolation 
and cellular and molecular characterization. Using gain and loss 
of Mesp1 function during ESC differentiation, we demonstrated 
that Mesp1 is required to promote the specification of MCPs 
and  the  expression  of  cardiovascular  transcription  factors  in 
MCPs. We found that Isl1 is expressed in a subpopulation of 
Mesp1­expressing cells and stimulates cardiovascular commit­
ment in these early MCPs. Our study provides novel insights 
into the cellular and transcriptional hierarchy acting during the 
early steps of cardiovascular differentiation.
Results
Mesp1-GFP–expressing cells represent the 
earliest source of cardiovascular 
progenitors during ESC differentiation
To  investigate  the  cellular  and  molecular  characteristics  of 
Mesp1­expressing cells during ESC differentiation, we gener­
ated an ESC line expressing Venus­GFP under the control of the 
5.6­kb  regulatory  region  upstream  of  the  Mesp1  coding  se­
quence, which faithfully recapitulates endogenous Mesp1 expres­
sion in the cardiogenic mesoderm of transgenic mice (Fig. 1 A; 
Haraguchi et al., 2001). We electroporated this Mesp1­GFP re­
porter construct into ESCs, isolated neomycin resistant clones, 
and selected several different Mesp1­GFP ESC clones present­
ing temporal expression of GFP that closely followed that of 
Mesp1 mRNA (Fig. 1, B–D). No GFP­positive cells were ob­
served in undifferentiated ESCs, but during ESC differentiation, 
Mesp1­GFP–positive cells appeared around day 2 (D2), peaked 
at D3, were maintained at D4, and rapidly decreased thereafter 
to become undetectable at D6 (Fig. 1 D). This transient expres­
sion of Mesp1­GFP during ESC differentiation is consistent 
with the early and transient expression of Mesp1 in the nascent 
mesoderm during embryonic development (Saga et al., 1996, 
1999).  Using  RT­PCR  analysis,  we  showed  that  Mesp1  and 
GFP transcripts are enriched in Mesp1­GFP–expressing cells 
isolated at the peak of Mesp1­GFP expression (D3) during ESC 
differentiation (Fig. 1, D and E), demonstrating that our Mesp1­
GFP reporter ESC line recapitulates the temporal endogenous 
expression of Mesp1.
To determine whether Mesp1­expressing cells contained 
the early cardiovascular progenitors, we isolated Mesp1­GFP–
expressing cells at D3 and cultured these cells in a serum­
free medium, allowing cardiac terminal differentiation in vitro 
(Kattman et al., 2006). After 8 d of culture, beating cells were 
greatly enriched in the Mesp1­GFP–derived cells (Video 1) com­
pared with GFP­negative (Video 2) or all sorted cells (Video 3).   
We analyzed and quantified the differentiation potential of 
Mesp1­GFP cells using FACS, immunostaining, and RT­PCR 
analysis and found that early Mesp1­expressing cells are en­
riched for progenitors with the potential to differentiate into 
CMs (marked by cardiac troponin T [cTNT] expression; Fig. 2 A), 
ECs (CD31; Fig. 2 B), and SMCs (smooth muscle actin [SMA]; 
During the spontaneous differentiation of embryonic stem 
cells (ESCs), cardiovascular cells are generated through a bio­
logical  process  that  recapitulates  the  cellular  and  molecular 
events normally occurring during embryonic development 
(Kattman et al., 2007; Murry and Keller, 2008). Using the same 
markers as to isolate the different MCPs during embryonic de­
velopment, mouse and human bipotent and tripotent MCPs have 
been isolated during ESC differentiation, giving rise to CMs, 
SMCs, and ECs similar to their in vivo potential (Kattman et al., 
2006; Moretti et al., 2006; Wu et al., 2006; Yang et al., 2008;   
Bu et al., 2009). The spontaneous appearance of cardiovascular 
cells during the differentiation of ESCs has created great enthu­
siasm among developmental biologists for studying, using 
reductionist in vitro approaches, the complex cellular and mo­
lecular  mechanisms  governing  cardiovascular  differentiation 
and cardiovascular diseases as well as providing a means of 
generating cardiovascular cells for cellular therapy and drug or 
toxicity screening (Murry and Keller, 2008).
Mesp1 is the earliest marker of cardiovascular develop­
ment in vivo (Saga et al., 2000; Bondue and Blanpain, 2010). 
Mesp1  is  expressed  very  transiently  during  early  mesoderm 
specification in the primitive streak that migrates anterolaterally 
along with the cardiac mesoderm (Saga et al., 1996, 1999). 
Mesp1 lineage tracing experiments in mice revealed that almost 
all cells of the future heart as well as cells of the main vessels 
derived from cells that had expressed Mesp1 at one point during 
embryonic development (Saga et al., 1999, 2000). In addition to 
being the earliest marker of cardiovascular development, Mesp1 
also plays a very important role during the earliest step of cardio­
vascular differentiation. Although genetic mutation of Mesp1 in 
mice does not lead to the absence of cardiac and vascular   
cells, possibly because the compensation is mediated by the 
massive up­regulation of its closest homologue Mesp2 (Saga   
et al., 1999; Kitajima et al., 2000), the combined deletion of 
Mesp1 and Mesp2 leads to the absence of mesoderm and car­
diac specification (Kitajima et al., 2000). Recently, we and   
others have shown that Mesp1 overexpression greatly promotes 
the generation of multiple cardiovascular cell lineages during 
ESC differentiation, including derivatives of FHF and SHF pro­
genitors  (Bondue  et  al.,  2008;  David  et  al.,  2008;  Lindsley   
et  al.,  2008).  Transcriptional  profiling  of  Mesp1­expressing 
cells combined with chromatin immunoprecipitation experiments 
revealed that Mesp1 directly and rapidly induces the expression 
of many transcription factors implicated in cardiovascular spec­
ification. (Bondue et al., 2008; Lindsley et al., 2008).
Although rapid progress is being made in characterizing 
MCPs of the FHF and SHF, little is known about their specifica­
tion. Do these MCPs arise from a common progenitor? If so, do 
these earliest MCPs represent a homogenous cell population 
common for both heart fields? What are the cell surface markers 
expressed by the early MCPs allowing their prospective isola­
tion? What are the transcription factors expressed by the early 
MCPs that act alone or in combination with Mesp1 to promote 
MCP specification and cardiovascular lineage differentiation? 
To address these questions, we generated Mesp1­GFP reporter 
ESCs that allowed tracking and isolation of the earliest Mesp1­
expressing cells during ESC differentiation. We showed that 753 The early step of cardiovascular progenitor specification • Bondue et al.
among them some colonies also expressed EC or CM markers, 
some colonies expressed markers of all three lineages, and 
Tbx5 and Isl1 were both expressed in 50% of the tripotent 
colonies (Fig. 2 G), supporting the notion that a fraction of 
Mesp1­expressing cells represents common progenitors for 
both heart fields.
To identify the other cell types into which Mesp1­GFP 
cells can differentiate, we analyzed the expression of a panel of 
markers that are representative of different cell lineages from 
the three germ layers. In addition to differentiating into cardio­
vascular cells, Mesp1­GFP cells could also differentiate into 
skeletal muscle and bone cells (Myogenin, Runx2, and Col1a1; 
Fig. S1 B), which is consistent with the in vivo Mesp1 lineage­
tracing experiments that showed that Mesp1­expressing cells give 
rise to some muscles and bones of the face (McBratney­Owen   
et al., 2008; Yoshida et al., 2008; Harel et al., 2009). However, 
not all mesoderm derivatives were increased in Mesp1­GFP 
cells; e.g., no increase in hematopoietic markers, such as Gata1 
and HoxB1, was observed.
To investigate the in vivo differentiation potential of the 
early Mesp1­GFP–expressing cells, we isolated these cells by 
FACS at D3 and transplanted them under the kidney capsule of 
nonobese diabetic/severe combined immunodeficient mice. 4 wk 
after their transplantation, no teratomas were observed, whereas 
Mesp1­GFP–negative cells, grafted under the other kidney   
capsule as a control, generated teratomas (unpublished data). 
Immunostaining of the grafts demonstrated that Mesp1­GFP 
cells mainly differentiated into CMs, although expression of EC 
Fig. 2 C and Fig. S1 A). Altogether, the three main lineages aris­
ing from the differentiation of MCPs represented 65% of all 
cells in Mesp1­GFP isolated cells. RT­PCR showed that Mesp1­
GFP–derived cells are enriched in cardiac transcription factors 
of the FHF and SHF (Nkx2-5, Gata4, Mef2c, Hand2, Tbx5, 
Tbx20, and Isl1); in pan­ (TropT2 and aMHC), atrial (Mlc2a), 
and ventricular (Mlc2v) cardiac markers; in epicardial markers 
(Tbx18 and Wt1); and EC markers (CD31; Fig. 2 D). These re­
sults demonstrate that Mesp1­GFP–expressing cells are greatly 
enriched in early MCPs and suggest that early Mesp1­expressing 
cells give rise to the previously described MCPs of the FHF and 
the  SHF  during  ESC  differentiation  (Kattman  et  al.,  2006; 
Moretti et al., 2006; Wu et al. 2006).
To determine whether Mesp1­expressing cells represent 
common progenitors for both heart fields, we performed clonal 
analysis of Mesp1­expressing cells isolated at D3. Immuno­
staining of individual colonies arising from the differentiation 
of single Mesp1­expressing cells showed that almost all colo­
nies contain SMA­positive cells, 15% of the clones presented 
both cardiac and vascular cells, 40% only expressed cTNT, and 
40% only expressed vascular endothelial (VE) cadherin (Fig. 2, 
E and F), although the proportion of cells expressing these dif­
ferent markers is influenced by the culture conditions (not de­
picted). To determine whether derivatives of the FHF and SHF 
are present within the tripotent colonies, we performed RT­PCR 
on colonies arising from the differentiation of a single Mesp1­
expressing cell. Similar to the results obtained by immuno­
staining, the vast majority of the colonies expressed SMA; 
Figure 1.  Engineering ESCs expressing Venus-GFP under the regulatory region of Mesp1. (A) Schematic representation of the Mesp1 reporter transgene. 
Venus-GFP is cloned under the regulatory sequences of Mesp1 that allowed transgene expression in the cardiogenic mesoderm. (B, right) Detection of GFP 
in Mesp1-GFP ESCs at D3 of differentiation. (left) Unmodified ESCs at the same day of differentiation are used as a control. Bars, 50 µm. (C and D) Kinetics of 
Mesp1 mRNA expression measured by RT–quantitative PCR (C), and Mesp1-GFP expression as detected by FACS (D). Results are normalized for Mesp1 
expression in undifferentiated ESCs (C) or represent the percentage of Mesp1-GFP–positive cells (D). (E) Relative expression of Mesp1 and GFP transcripts 
in Mesp1-GFP–expressing cells (GFP positive [pos]) and in Mesp1-GFP–nonexpressing cells (GFP negative [neg]) isolated by FACS at D3. Results are nor-
malized for the expression of the transcripts in all sorted cells (gray bars). Error bars indicate means ± SEM; n = 3. FRT, flippase recognition target. 
pA, polyadenylation. PGK, phosphoglycerate kinase.JCB • VOLUME 192 • NUMBER 5 • 2011   754
Figure 2.  Isolation and functional characterization of early Mesp1-GFP–expressing cells. (A–C) Expression of cardiovascular markers after 8 d of differ-
entiation of the indicated cell populations isolated at D3. Cardiac and endothelial differentiation were quantified by FACS using a cardiac-specific isoform 
of the troponin T (cTNT; A) and the endothelial marker CD31 (B). SMC differentiation was assessed by counting the percentage of cells expressing smooth 755 The early step of cardiovascular progenitor specification • Bondue et al.
microarray analysis to define the molecular signature of Mesp1­
GFP–expressing cells during ESC differentiation. We determined 
which genes displayed a change in expression of ≥1.5­fold be­
tween Mesp1­GFP–positive and –negative cells at D3 of ESC 
differentiation in two separate biological replicates. Using these 
criteria, we found that 1,151 probes out of 45,101 presented a 
differential  expression  between  Mesp1­positive  and  Mesp1­
negative cells. Among them, 281 probes were found to be up­
regulated  in  Mesp1­expressing  cells,  corresponding  to  212 
unique annotated genes (Table I). In addition to the differen­
tially expressed genes found in our duplicate microarray analyses, 
and SMC markers was also present within the graft (Fig. 2 H). 
Altogether these data show that Mesp1­expressing cells contain 
the earliest MCPs specified during ESC differentiation, which 
give rise upon differentiation to CMs, ECs, and SMCs in vitro 
and in vivo, and a fraction of Mesp1­expressing cells represent 
common progenitors for FHF and SHF MCPs.
Transcriptional profiling of early Mesp1-GFP 
cells during ESC differentiation
To better characterize the early molecular events occurring in 
Mesp1­expressing cells during MCP specification, we used   
muscle actin (SMA) on cytospin slides (C; also see Fig. S1 A). n = 4. (D) Relative mRNA expression of cardiovascular markers in Mesp1-GFP positive– 
derived cells (black bars) and in all sorted cells (gray bars) assessed by real-time RT-PCR 8 d after replating. Results are normalized to the expression of the 
different transcripts in the Mesp1-GFP negative (Neg)–derived cells (white bars). n = 4. (E) Immunostaining for cTNT (CMs), VE-cadherin (VE-cadh; ECs), and 
SMA (SMCs) in individual colonies obtained after the replating at the clonal density of isolated Mesp1-GFP cells at D3 and cultured for 13 d. Bars, 50 µm. 
(F) Quantification of colonies expressing cardiovascular (cTNT and VE-cadherin), cardiac (cTNT), and endothelial (VE-cadherin) markers as obtained in E.   
n = 3. (G) RT-PCR analysis of cardiovascular markers in colonies derived from a single Mesp1-GFP isolated cell in 96 wells after 13 d of differentiation. Only 
clones positive for -actin are shown, with dividing lines indicating the removal of intervening lanes from the gels. Samples tested in different experiments 
are shown as distinct panels with their respective positive (+) and negative () control samples. (H) Cardiovascular potential of Mesp1-GFP isolated cells at 
D3 of ESC differentiation, which were transplanted under the kidney capsule of nonobese diabetic/severe combined immunodeficient mice. Cardiovascular 
differentiation was assessed after 4 wk by immunostaining for cTNT, VE-cadherin, and SMA. n = 3. Bars, 100 µm. Error bars indicate means ± SEM.
 
Table I.  Microarray analysis of Mesp1-GFP–expressing cells
Category Up-regulated genes
Transcription factors and 
chromatin remodeling
Hoxb1 (3.7), Foxc1* (3.5), Lmo1 (3.2), Foxc2* (3.0), Foxf1a (2.9), Pdlim4 (2.9), Isl1 (2.8),  
Hoxb2 (2.6), Mesp1 (2.6), Etv2 (2.4), Prrx2 (2.4), Tbx3 (2.4), Tbx6 (2.4), Snai1 (2.4), Lef1 (2.3),  
Msx2 (2.3), Smarcd3 (2.3), Mesp2 (2.2), Tbx2 (2.2), Evx1 (2.1), Hand1 (2.1), Meis2 (2.1), Prdm6 (2.1),  
Zcchc12 (2.1), Gata4 (2), Hand2 (2), Klhl6 (2), Msx1 (2), Six2 (2), Twist1* (2), Vax1 (2), Zeb2* (2),  
Bhlhe22 (1.9), Tbx20 (1.9), Zbtb7c (1.9), Ets1 (1.9), Hey2* (1.9), Smad6* (1.9), Zdhhc20* (1.9),  
Zcchc24* (1.9), Hmga2 (1.8), Hoxd1 (1.8), Pdlim5 (1.8), Tshz1 (1.8), Zfp516 (1.8), Hey1* (1.7),  
Smad1 (1.7), Cbx4 (1.7), Zfp423 (1.7), Foxh1 (1.6), Nfatc1* (1.6), Twist2* (1.6), Zeb1* (1.6)
Signaling pathways  
(other than receptors)
Notch Dll1 (2.1), Dll3 (2.0), Hey2 (1.9), Hey1 (1.7)
Wnt Wnt5a (3), Wnt2 (2.8), Wnt5b (2.1), Apcdd1 (1.8), Lef1 (1.8), Wnt3 (1.7)
FGF Fgf3 (2.3), Fgf15 (1.7), Fgf10 (1.6)
TGF-b Gdf10 (2.7), Tgfb2 (2.0), Lefty2 (1.9), Tgfbi (1.9), Tgfb1i1 (1.8), Vasn (1.7)
Bmp Bmper (2.4), Bmp4 (2.0), Bambi (1.7), Bmp6 (1.6), Smad6 (1.9), Smad1 (1.6)
Others Rasgrp3 (2.4), Rgs5 (2.7), Crabp1 (2.7), Htr1d (2.6), Adcyap1r1 (2.5), S1pr5 (2.4), Ptgds (2.3),  
Dusp9 (2.3), Cap2 (2.0), Dlc1 (1.9), Tnfsf13b (1.9), Adcy3 (1.9), Dok4 (1.9), Efna3 (1.8), Braf (1.7),  
Prkd1 (1.7), Alox15 (1.6), Pgr (1.6), Vegfc (1.6)
Membrane proteins  
and receptors
Pcdh19 (3.1), Pdgfra (3.1), Ceacam10 (2.9), Cmklr1 (2.5), Gp1bb (2.5), Plac1 (2.5), Cacna1c (2.4),  
Odz4 (2.3), Nrp2 (2.3), Vldlr (2.3), Cdh4 (2.3), Pcdh18 (2.3), Adrb1 (2.2), Kdr (2.1), Rftn1 (2.1),  
Unc5c (2.1), Lhfp (2.0), Kcnd3 (2.0), Il13ra1 (2.0), Amhr2 (2.0), Cd160 (1.9), L1cam (1.9), Cxcr4 (1.9),  
Aplnr (1.9), Pcdh7 (1.9), Cxcr7 (1.9), Slc4a4 (1.9), Gpr177 (1.8), Itga8 (1.8), Prtg (1.8), Ednra (1.8),  
Kcnc1 (1.8), Cdh11 (1.7), Pcdh7 (1.7), Pdgfrb (1.7), Gfra2 (1.7), Trpc3 (1.7), Nrp1 (1.7), Cdh2 (1.7),  
Tmem88 (1.6), Il1rap (1.6), Lrp1 (1.6), Ms4a4d (1.6), Kctd15 (1.5)
Extracellular matrix Col6a1 (3.5), Col9a1 (2.6), Emid2 (2.4), Leprel1 (2.3), Fbln2 (2.2), Fbln7 (2.1), Lor (2.0), Col13a1 (2.0),  
Fn1 (1.9), Has2 (1.8), Vcan (1.6), Flnb (1.6), Mmp2 (1.6)
Others Spp1 (5.8), Fabp4 (5.5), H60a (4.5), Ugt1a1 (4.0), Papss2 (3.8), Agpat9 (3.1), Ccdc109b (2.8),  
Phlda2 (2.6), Egln3 (2.5), Gna14 (2.5), Pcsk5 (2.4), Atp1a2 (2.4), Dock10 (2.3), Hs3st3b1 (2.3),  
Morc4 (2.3), Chst2 (2.3), Pmp22 (2.3), Adamts20 (2.2), St6galnac4 (2.2), Exoc3l (2.2), Fam123c (2.1),  
Myl7 (2.1), Prdm6 (2.1), Susd5 (2.1), Rbm24 (2.1), Siah2 (2.1), Mex3b (2.1), Chst7 (2.0), Nin (2.0),  
Actc1 (2.0), Kif26b (2.0), Ccnd2 (2.0), Itih5 (1.9), Man1c1 (1.9), Cbln1 (1.9), Mn1 (1.9), Sh3bp1 (1.9),  
Fam82a1 (1.8), Olfm1 (1.8), Serpinb9 (1.8), Cdkn1c (1.8), Phldb2 (1.8), Pmaip1 (1.8), Gas1 (1.8),  
Abtb2 (1.8), Adamts3 (1.7), Sgcb (1.7), Sbsn (1.7), Cyp2s1 (1.7), Adam19 (1.7), Brp44 (1.7),  
Cyp4f15 (1.7), Dclk1 (1.7), Slco3a1 (1.7), Bace2 (1.7), Car3 (1.7), Aard (1.6), Oaf (1.6), Zadh2 (1.6),  
As3mt (1.6), Grrp1 (1.6), Ablim1 (1.6), Fam122b (1.6), Gne (1.6), Ptprm (1.6), Rps6ka6 (1.6), Lmna (1.5),  
Man1a (1.5), Pwwp2b (1.5)
Fold changes are indicated in parentheses. Asterisks indicate genes found only in one of the two array replicates and confirmed by RT-PCR on different biological 
samples. Bold indicates genes found to be also up-regulated after Mesp1 overexpression.JCB • VOLUME 192 • NUMBER 5 • 2011   756
Figure 3.  Isolation and functional characterization of early MCPs using a combination of monoclonal antibodies. (A) Cell surface marker expression in 
Mesp1-GFP–expressing cells as measured by real-time RT-PCR in isolated Mesp1-GFP–expressing cells at D3. Results are normalized for the mRNA expres-
sion in GFP-negative cells. n = 3. (B) Detection of CXCR4, PDGFRa, and Flk1 by FACS at D3 in all living cells (top) and in the Mesp1-GFP population (bottom). 757 The early step of cardiovascular progenitor specification • Bondue et al.
at D3 were enriched for Mesp1 mRNA (Fig. 3 D), and these 
triple­positive (TP) cells presented a temporal appearance 
(Fig.  3,  E  and  F)  similar  to  Mesp1­GFP–expressing  cells 
(Fig. 1 D), strongly suggesting that this combination of cell sur­
face markers mirrors well the endogenous Mesp1 expression.
To determine whether the CXCR4/PDGFRa/Flk1 TP cells 
are enriched in early MCPs during ESC differentiation, we iso­
lated TP cells by FACS at D3 and cultured them in a serum­free 
medium for a supplemental 8 d. Similar to what we found for 
the differentiation of Mesp1­expressing cells, beating cells were 
preferentially observed in TP cells compared with all sorted 
cells and triple negative cells. Quantification of cardiac and vascu­
lar differentiation revealed that TP cells were similarly enriched 
in CM (Fig. 3 G), EC (Fig. 3 H), and SMC (Fig. 3 I and Fig. S1 C) 
differentiation as Mesp1­GFP–expressing cells (Fig. 2, A–C), sug­
gesting that the combination of these three monoclonal antibodies 
closely tracks with Mesp1 expression at the time of MCP speci­
fication and can be used to monitor and isolate early MCPs 
during ESC differentiation.
To determine how Mesp1­expressing cells are related to 
the previously described Bry­GFP
+/Flk1
+ MCPs (Kattman et al., 
2007), we analyzed the expression of Mesp1 and CXCR4, 
PDGFRa, and Flk1 in Bry­GFP/Flk1–expressing cells at differ­
ent times of ESC differentiation (Fig. S3). At D3, Bry­GFP/Flk1–
expressing cells can be separated into two distinct populations, 
one coexpressing CXCR4, PDGFRa, and Flk1 and the other   
expressing Flk1/CXCR4 but negative for PDGFRa (Fig. S3 B). 
Mesp1 was enriched to a similar level in CXCR4/PDGFRa/Flk1 TP 
cells and in Bry­GFP/Flk1/PDGFRa TP cells, whereas no Mesp1 
enrichment  was  found  in  Bry­GFP
+/Flk1
+/PDGFRa–negative   
cells (Fig. S3 D). In contrast, Scl, a marker of hemangioblast lin­
eage,  was  strongly  enriched  in  Bry­GFP
+/Flk1
+/PDGFRa– 
negative  cells  but  not  in  CXCR4/PDGFRa/Flk1  TP  or  in 
Bry­GFP/Flk1/PDGFRa–positive cells. These data indicated 
that Mesp1­expressing cells correspond to a subpopulation of 
the previously described Bry­GFP/Flk1–positive progenitors.
Mesp1 rapidly promotes and is  
required for MCP specification  
during ESC differentiation
Using Mesp1 gain of function in ESCs, we and others have pre­
viously shown that Mesp1 expression greatly increased and ac­
celerated the differentiation of ESCs into cardiac, vascular, and 
smooth muscle lineages (Bondue et al., 2008; David et al., 2008; 
Lindsley et al., 2008). The increase in cells expressing Flk1 and 
PDGFRa after Mesp1 expression (Lindsley et al., 2008) sug­
gests that Mesp1 expression can promote MCP specification. To 
determine whether Mesp1 rapidly promotes MCP specification, 
we assessed the relative frequency of CXCR4/PDGFRa/Flk1 
TP cells at different early time points after Mesp1 expression 
a certain number of genes were found to be up­regulated in 
only one of the two replicates, probably because of low level 
expression, but were confirmed by RT­PCR on different biolog­
ical replicates.
Functional annotation clustering of the 212 probes up­
regulated  in  the  duplicate  microarray  analysis  of  Mesp1­ 
expressing cells at D3 was performed using the Database for 
Annotation, Visualization, and Integrated Discovery bioinfor­
matics resources (Huang et al., 2009). The functional annota­
tion chart revealed that the first term retrieved in Mesp1­enriched 
genes is heart development (10% of the genes) followed by 
muscle, embryonic, mesoderm, tube, blood vessel, and vascula­
ture development (Table S1).
We have recently demonstrated that Mesp1 overexpres­
sion rapidly promotes the expression of many genes implicated 
in cardiovascular development (Bondue et al., 2008). To deter­
mine  which  of  these  genes  are  naturally  expressed  within 
Mesp1­expressing cells during ESC differentiation, we compared 
the list of genes up­regulated upon Mesp1 gain of function with 
the genes enriched in Mesp1­GFP–expressing cells at D3 and 
found that 35% of the genes up­regulated by Mesp1 over­
expression  were  also  gene  enriched  in  Mesp1­GFP–expressing 
cells (Table I). To validate the significance of this enrichment, 
we compared the fold change direction of the probes that were 
significantly  up­regulated  or  down­regulated  in  Mesp1­GFP 
cells and after Mesp1 overexpression. The proportion of coher­
ent genes (27%), in which the probe is affected in the same di­
rection in Mesp1­GFP cells and after Mesp1 gain of function, is 
significantly much higher than the incoherent ones (3%; Fig. S2). 
These data reinforced the notion that Mesp1 directly or indi­
rectly controls a significant proportion of the cardiac differenti­
ation program during ESC differentiation.
Isolation and functional characterization of 
Mesp1-expressing cells using a combination 
of monoclonal antibodies
Our  microarray  and  RT­PCR  analysis  of  Mesp1­expressing 
cells  demonstrated  that  early  MCPs  preferentially  express  a   
variety of cell surface proteins (Fig. 3 A and Table I). Among 
them, only CXCR4, PDGFRa, or Flk1, which have previously 
been associated with later stages of cardiovascular progenitors 
during  ESC  differentiation  (Iida  et  al.,  2005;  Moretti  et  al., 
2006; Nelson et al., 2008; Hidaka et al., 2010), was expressed at 
a high level in almost all Mesp1­GFP–expressing cells at D3 
(Fig. 3 B). At this time point, Mesp1­expressing cells consisted 
of a relatively homogenous population of cells coexpressing a 
high level of CXCR4, PDGFRa, and Flk1, whereas 24 h later at 
D4, Mesp1­expressing cells were more heterogeneous with   
regard to the level of expression of these markers (Fig. 3 C). 
Cells coexpressing high levels of CXCR4, PDGFRa, and Flk1 
(C) Multicolor FACS analysis gated on Mesp1-GFP cells of CXCR4, PDGFRa, and Flk1 expression at D3 and D4. (D) Enrichment of Mesp1 expression in TP 
cells at D3 as measured by RT-PCR on FACS-isolated cells. Results are normalized for the relative transcript expression in all sorted cells. n = 3. (E) Temporal 
expression of CXCR4, PDGFRa, and Flk1 during ESC differentiation as detected by FACS. n = 2. (F) Combined detection of CXCR4, PDGFRa, and Flk1 
expression at D3 and D4 in all living cells. (C and F) Percentages of cells in each quadrant are shown, and the percentage of CXCR4/PDGFRa/Flk1 TP 
cells are shown in parentheses. (G–I) Cardiac (G), endothelial (H), and SMC (I; also see Fig. S1 C) differentiation of TP cells as performed in Fig. 2 (A–C).   
n = 4. Error bars indicate means ± SEM.
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to directly measure cell proliferation and apoptosis within the 
PDGFRa
+/Flk1
+ population after Mesp1 gain of function. Mesp1 
expression did not increase cell proliferation (Fig. 4 D) or apop­
tosis (Fig. 4 E) in PDGFRa
+/Flk1
+­positive cells, which is consis­
tent with previous observations suggesting that Mesp1 promotes 
MCP specification through an instructive rather than selective 
mechanism (Bondue et al., 2008; Lindsley et al., 2008).
To determine whether Mesp1 is required for MCP speci­
fication during ESC differentiation, we generated an ESC line   
allowing inducible expression of a fusion protein of Mesp1   
with the repressor domain of Drosophila melanogaster Engrailed 
using a doxycyclin (Dox)­inducible Mesp1 ESC line (Fig. 4 A). 
We added Dox at D2 of ESC differentiation and monitored the 
expression of TP cells after 24 and 48 h. As early as 24 h after 
Dox addition, a major increase in the proportion of the TP cell 
population was observed in Mesp1­overexpressing cells com­
pared with unstimulated Mesp1 ESCs (Fig. 4 B). This effect 
persisted and increased 48 h after Dox addition (Fig. 4 C), 
showing that forced expression of Mesp1 during ESC differen­
tiation rapidly promotes MCP specification.
To determine whether Mesp1 promotes MCP specification 
through a selective mechanism, we used multicolor FACS analysis 
Figure  4.  Mesp1  rapidly  promotes  and  is   
required  for  MCP  specification  and  cardiac   
differentiation. (A) Schematic representation of 
Dox-inducible Mesp1 ESCs. (B) FACS analy-
sis of the expression of CXCR4, PDGFRa, and 
Flk1 in Mesp1 Dox-inducible ESCs at D3, 24 h 
after Dox addition. (C) FACS quantification of 
CXCR4/PDGFRa/Flk1 TP cells in Mesp1 Dox-
inducible ESCs 24 (D3) and 48 h (D4) after 
Dox addition. n = 3. (D and E) FACS quantifi-
cation of proliferation (BrdU; D) and apoptosis 
(active caspase-3; E) in PDGFRa
+/Flk1
+ cells 
and in all Mesp1-inducible ESCs in the pres-
ence and absence of Dox for 24 h (D3). n = 2. 
(F) Schematic representation of Dox-inducible 
Engrailed  (Engr)-Mesp1  ESCs  (EN-Mesp1). 
(G) FACS analysis of CXCR4, PDGFRa, and 
Flk1 expression in EN-Mesp1–inducible ESCs 
at D4, 48 h after Dox addition. (B and G) Per-
centages of cells in each quadrant are shown, 
and the percentage of CXCR4/PDGFRa/Flk1 
TP cells are shown in parentheses. (H) FACS 
quantification of TP cells in EN-Mesp1–inducible   
ESCs 24 (D3) and 48 h (D4) after Dox add-
ition. Results are normalized to unstimulated 
cells. n = 3. (I) Quantification of beating areas   
in EN-Mesp1 ESCs in the presence or in the 
absence of Dox at D8. n = 3. (J and K) FACS 
quantification  of  cTNT  (J)  and  CD31  (K)  in 
EN-Mesp1–expressing cells. n = 3. Error bars   
indicate  means  ±  SEM.  TRE,  tetracycline- 
responsive element. EB, embryoid body.759 The early step of cardiovascular progenitor specification • Bondue et al.
multiple cardiac transcription factors at the same time in the 
same cell (Fig. 5 F). In addition, overexpression of EN­Mesp1 
down­regulated  the  expression  of  these  transcription  factors 
(Fig. 5 G). Altogether, these data strongly suggest that Mesp1 
directly or indirectly controls the expression of many key   
cardiovascular transcription factors in MCPs and increases the 
probability of cardiac commitment in individual cells.
Isl1 is expressed independently of Mesp1 in 
a subset of early Mesp1-expressing cells
Isl1  expression  has  been  previously  used  to  mark  tripotent 
MCPs at D5 of ESC differentiation (Moretti et al., 2006). Isl1 is 
expressed in SHF progenitors and is required for SHF develop­
ment (Cai et al., 2003), although recent studies reported Isl1 ex­
pression in embryonic regions corresponding to the FHF (Brade   
et al., 2007; Prall et al., 2007). It remains unclear whether Isl1 
is also expressed earlier during ESC differentiation at the time 
of MCP specification. Our microarray and RT­PCR analysis re­
vealed that Mesp1­expressing cells are enriched for the Isl1 
transcript as early as D3 of ESC differentiation (Fig. 5 A and 
Table I). In contrast to direct or indirect Mesp1 target genes, Isl1 
is enriched in Mesp1­expressing cells (Fig. 5 A) and in TP 
cells (Fig. 5 D) but is not up­regulated by Mesp1 overexpres­
sion (Fig. 5 E) or down­regulated after EN­Mesp1 expression   
(Fig. 5 G), strongly suggesting that Isl1 is expressed in early 
MCPs independently of Mesp1.
To better characterize the relation between Mesp1 and 
Isl1  expression,  we  performed  immunostaining  for  Isl1  and 
GFP expression on cytospin preparations of Mesp1­GFP cells 
after ESC differentiation. Mesp1­GFP was expressed in 4 and 
1.5% of cells at D3 and D4, respectively (Fig. 6 A). Although 
the level of Isl1 expression was lower than in later stages of dif­
ferentiation, Isl1 expression was already detected at D3 and D4 
in 10% of cells (Fig. 6 B). At D3, 20% of Mesp1­expressing 
cells coexpressed Isl1 (Fig. 6, C and E). At D4, the level of Isl1 
expression increased, and 50% of Mesp1­expressing cells co­
expressed Isl1 (Fig. 6, D and E). The Mesp1/Isl1 double­
positive cells represent 10 and 6% of Isl1­expressing cells at D3 
and D4, respectively (Fig. 6 F). These data show that Isl1 is co­
expressed together with Mesp1 in a fraction of early Mesp1­ 
expressing cells.
Isl1 cooperates with Mesp1 to promote 
endothelial or cardiac cell lineage 
commitment, depending on the stage of 
cardiovascular differentiation
To determine the functional consequences of Isl1 expression 
in Mesp1­expressing cells, we generated an ESC line that al­
lows Dox­inducible expression of Isl1 alone or in combination 
with Mesp1 (Fig. 7 A). Dox administration in Isl1­inducible 
ESCs increased transgene expression to a similar level and in 
the same proportion of cells as in the Mesp1­inducible ESCs 
(Fig. S4). Isl1 overexpression during the early stage of ESC 
differentiation (D2 and D3), corresponding to the time of MCP 
specification, did not increase the proportion of the CXCR4/
PDGFRa/Flk1 TP cells at D3 or D4, and the coexpression of 
Mesp1 and Isl1 had no additive or synergistic effect compared 
(EN; EN­Mesp1; Fig. 4 F; Han and Manley, 1993). Transient ex­
pression of EN­Mesp1 at D2 and D3 led to a complete absence of 
CXCR4/PDGFRa/Flk1 TP cells (Fig. 4, G and H), a complete ab­
sence of beating cells (Fig. 4 I), a dramatic reduction in CM differ­
entiation (Fig. 4 J), and a significant reduction in EC differentiation 
(Fig. 4 K), showing that Mesp1 is required for MCP specification 
and cardiovascular differentiation during ESC differentiation.
Mesp1 regulates the expression 
of cardiovascular and epithelial 
to mesenchymal transition (EMT) 
transcription factors in MCPs
Our microarray analysis of Mesp1­GFP–expressing cells dur­
ing ESC differentiation showed that many key transcription fac­
tors involved in early cardiovascular development are enriched 
in Mesp1­GFP–expressing cells (Fig. 5 A and Table I). A large 
fraction  of  these  transcriptional  regulators  were  previously 
shown to be up­regulated upon Mesp1 expression, whereas   
others were not affected (i.e., Isl1) or even down­regulated (i.e., 
Mesp2) after Mesp1 gain of function (Bondue et al., 2008). In 
addition to the cardiovascular transcription factors, several tran­
scription factors mediating EMT, such as Snail1, Twist1/2, and 
Foxc1/2  (Fig.  5  B),  were  also  up­regulated  in  Mesp1­GFP– 
expressing cells. Indeed, the vast majority of Mesp1­GFP cells 
expressed low levels of epithelial (E) cadherin, which is consis­
tent with the notion that Mesp1­GFP cells undergo EMT during 
MCP specification (Fig. 5 C). RT­PCR analysis performed on 
FACS­isolated  CXCR4/PDGFRa/Flk1  TP  cells  showed  that 
MCPs isolated using monoclonal antibodies present a similar 
enrichment for the expression of cardiovascular transcriptional 
regulators compared with Mesp1­GFP cells (Fig. 5 D), some of 
which (Hand1, Hand2, Nkx2-5, Gata6, and Tbx20) increased 
between D3 and D4, suggesting that early specified MCPs   
undergo a progressive maturation toward cardiovascular differ­
entiation over time.
We have recently demonstrated that Mesp1 rapidly pro­
motes the expression of many transcription factors involved in 
cardiovascular differentiation during ESC differentiation and 
have shown that some of these genes are direct Mesp1 target 
genes (Bondue et al., 2008). To determine to which extent the 
up­regulation of these transcription factors is regulated by 
Mesp1, we measured the expression of these cardiovascular 
transcription factors in CXCR4/PDGFRa/Flk1 TP cells after 
Mesp1 overexpression. These data showed that Mesp1 overexpres­
sion further increased the level of expression of cardiovascular 
transcription  factors,  such  as  Hand2,  Myocardin,  or  Nkx2-5, 
within the CXCR4/PDGFRa/Flk1 TP population (Fig. 5 E). To 
determine whether the increase in the expression of these tran­
scription factors was the consequence of a homogenous change 
in gene expression mediated by Mesp1 in the entire TP cell 
population or whether Mesp1 only up­regulated the expression 
of these transcriptions in a fraction of these cells, we performed 
single­cell RT­PCR on FACS­isolated CXCR4/PDGFRa/Flk1 
TP cells after Mesp1 gain of function. In the absence of Mesp1 
overexpression, the vast majority of TP cells only expressed one 
or the other cardiac transcription factors, whereas upon Mesp1 
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Figure 5.  Cardiovascular and EMT transcription factors regulated by Mesp1 in early MCPs. (A and B) Real-time RT-PCR analysis of mRNA relative expres-
sion of cardiovascular (A) and EMT (B) transcription factors in FACS-isolated Mesp1-GFP cells at D3 (black bars). Results are normalized for the transcript 
expression in Mesp1-GFP–negative (Neg) cells (white bars). (C) E-Cadherin expression in all cells and in Mesp1-expressing cells as measured by FACS. 761 The early step of cardiovascular progenitor specification • Bondue et al.
cells represent a common progenitor for the MCPs of both heart 
fields, which appears several days later (between D5 and D6; 
Fig. 8; Moretti et al., 2006; Wu et al., 2006). Our data suggest 
that Mesp1­expressing cells represent a subpopulation of the 
previously  identified  Bry­GFP/Flk1  MCPs  (Kattman  et  al., 
2006). Bry­GFP/Flk1–expressing cells can be subdivided into 
two subpopulations: one negative for PDGFRa and repre­
senting hemangioblast progenitors and another expressing high 
levels of PDGFRa, corresponding to the Mesp1­enriched popu­
lation (Fig. 8).
The transcriptional profiling of early Mesp1­expressing 
cells identified cell surface markers that can be used in combi­
nation to enrich for Mesp1­expressing cells during ESC differ­
entiation and represent an ideal method to monitor and isolate 
the early MCPs generated during ESC differentiation. Interest­
ingly, these markers have been previously reported to be expressed 
by progenitors of later stages of cardiovascular differentiation 
(Iida et al., 2005; Moretti et al., 2006; Nelson et al., 2008; 
Hidaka et al., 2010). PDGFRa and Flk1 are expressed in the 
cardiac crescent in vivo (Ema et al., 2006; Prall et al., 2007; 
with Mesp1 expression alone (Fig. 7, B and C). Early expres­
sion of Isl1 during ESC differentiation only moderately pro­
moted cardiac differentiation (Fig. 7, D and E) but strongly 
increased endothelial differentiation (Fig. 7, F and G). Com­
bined expression of Mesp1 and Isl1 further increased endothe­
lial  differentiation  compared  with  Mesp1  alone  (Fig.  7  F). 
Overexpression of Isl1 during later stages of differentiation 
(between D5 and D6) did not promote vascular differentiation 
but increased cardiac differentiation, which was further en­
hanced by Mesp1 expression (Fig. 7, H and I).
Discussion
Our  study  revealed  that,  during  ESC  differentiation,  early 
Mesp1­GFP–expressing cells are greatly enriched for progeni­
tors with the ability to differentiate into the different cardiovas­
cular  cell  lineages  both  in  vitro  and  in  vivo,  similar  to  the 
differentiation potential of Mesp1 found in vivo. Clonal analy­
sis revealed that Mesp1­expressing cells differentiate into both 
FHF  and  SHF  derivatives,  indicating  that  Mesp1­expressing 
(D) Real-time RT-PCR analysis of the expression of cardiovascular transcription factors in CXCR4/PDGFRa/Flk1 TP cells isolated at D3 (white bars) and D4 
(black bars). Results are normalized for the mRNA expression in CXCR4
/PDGFRa
/Flk1
 cells. Numbers at the top of the bars indicate the fold change. 
(E) Real-time RT-PCR analysis of the expression of cardiovascular transcription factors within the TP population in Dox-inducible Mesp1 ESCs isolated   
at D4 in the presence or in the absence of Dox for 48 h. Results are normalized for transcript expression in unstimulated TP cells. (F) RT-PCR analysis of 
cardiovascular transcription factor expression in single TP isolated cells from Mesp1-inducible ESCs in the presence or in the absence of Dox for 48 h. Only 
clones positive for -actin are shown, with dividing lines indicating the removal of intervening lanes from the gels. Samples tested in different experiments 
are shown as distinct panels with their respective positive (+) and negative () control samples. (G) Expression of cardiovascular transcription factors in 
Dox-inducible EN-Mesp1 ESCs at D3. Results are normalized for the expression in Dox-untreated cells. Error bars indicate means ± SEM (n = 3).
 
Figure 6.  Isl1 is expressed in a subset of early Mesp1-expressing cells. (A and B) Quantification of Mesp1-GFP (A) and Isl1 (B) expression as measured 
by immunostaining of GFP and Isl1 on cytospin slides of Mesp1-GFP cells at D3 and D4. n = 3. (C and D) Confocal microscopy analysis of GFP (Mesp1) 
and Isl1 immunostaining in Mesp1-GFP cells at D3 (C) and D4 (D). (right) Magnification of the insets, and arrows indicate cells that coexpress Mesp1 and 
Isl1. Bars, 30 µm. (E and F) Quantification of Isl1 expression in Mesp1-GFP–expressing cells (E), and Mesp1 (GFP) expression in Isl1-expressing cells (F) at 
D3 and D4. More than 300 cells were counted in each condition. n = 3. Error bars indicate means ± SEM.JCB • VOLUME 192 • NUMBER 5 • 2011   762
Figure 7.  Isl1 and Mesp1 cooperate in promoting cardiovascular differentiation in ESCs. (A) Schematic representation of Mesp1, Isl1, and Mesp1/Isl1 
Dox-inducible ESCs. (B) FACS analysis of CXCR4, PDGFRa, and Flk1 expression in Isl1-inducible ESCs at D4, 48 h in the presence or absence of Dox 
treatment. Percentages of cells in each quadrant are shown, and the percentage of CXCR4/PDGFRa/Flk1 TP cells are shown in parentheses. (C) FACS 763 The early step of cardiovascular progenitor specification • Bondue et al.
ESC differentiation revealed that Isl1 cooperates with Mesp1 to 
promote cardiovascular differentiation. Isl1 promotes endothe­
lial fate at the early step of MCP specification and stimulates 
cardiac  differentiation  during  latter  stages,  and  these  effects 
were additive with those mediated by Mesp1, suggesting that 
Mesp1 and Isl1 cooperate to promote cardiovascular lineage 
commitment  and  control  distinct  transcriptional  programs  at 
different  stages  of  cardiovascular  differentiation.  Consistent 
with the cardiac­promoting effect of late Isl1 overexpression, 
loss of Isl1 function in differentiating ESC inhibits cardiac dif­
ferentiation (Kwon et al., 2009).
Our study provides novel insights into the cellular and 
transcriptional hierarchy that operates during the early step 
of  cardiovascular  progenitor  specification  and  provides  a 
means of isolating cardiovascular progenitors during ESC 
differentiation, increasing the generation of cardiac cells in 
vitro  for  cellular  therapy  or  drug  screening.  Mesp1­GFP 
ESCs will be a powerful method to screen for new intrinsic 
and extrinsic regulators of cardiovascular progenitor specifi­
cation and differentiation.
Takakura et al., 1997), and lineage tracing has shown that 
Flk1­expressing cells give rise to all cardiovascular lineages 
(Ema et al., 2006), suggesting that these markers could be used 
in future studies to isolate the early MCPs during mouse embry­
onic development.
Isl1 is expressed in the SHF progenitors during embryonic 
development, and Isl1 expression can be used to isolate tri­
potent  MCPs  during  mouse  and  human  ESC  differentiation 
(Moretti et al., 2006; Bu et al., 2009). Our study revealed that a 
fraction of Mesp1­GFP–expressing cells coexpressed Isl1 inde­
pendently of Mesp1. Interestingly, in Ciona intestinalis, a prim­
itive chordate, a fraction of Mesp1­expressing cells coexpresses 
Isl1 (Stolfi et al., 2010), suggesting that the expression of Isl1 in 
a subpopulation of the Mesp1 field has been conserved through­
out vertebrate evolution. In vertebrates, several recent studies 
showed that Isl1 is expressed transiently in the progenitor of the 
FHF  during  embryonic  development,  and  some  Isl1­derived 
cells can give rise to both FHF and SHF derivatives (Brade   
et al., 2007; Prall et al., 2007; Sun et al., 2007; Ma et al., 2008). 
Isl1 and Mesp1 gain­of­function studies at different times of 
quantification of CXCR4/PDGFRa/Flk1 TP cells at 24 (D3) and 48 h (D4) in the presence or absence of Dox in Mesp1, Isl1, and Mesp1/Isl1 Dox-inducible 
ESCs. n = 4. (D) FACS quantification of cTNT expression at D8 in Mesp1, Isl1, and Mesp1/Isl1 Dox-inducible ESCs in the presence or absence of Dox 
from D2 to D4. n = 4. (E) Immunostaining of cTNT at D8 of differentiation in Dox-inducible Mesp1, Isl1, and Mesp1/Isl1 ESCs in the presence or absence 
of Dox from D2 to D4. Images shown are mosaïc acquisitions representative of at least four biologically independent experiments. Bars, 500 µm. (F) FACS 
quantification of CD31 expression at D7 in Mesp1, Isl1, and Mesp1/Isl1 Dox-inducible ESCs in the presence or absence of Dox from D2 to D4. n = 4. 
(G) Immunostaining for VE-Cadherin expression at D7 in Dox-inducible Mesp1, Isl1, and Mesp1/Isl1 ESCs in the presence or absence of Dox from D2 to 
D4. Images shown are representative of four biologically independent experiments. Bars, 100 µm. (H and I) FACS quantification of cTNT (H) and CD31 
expression (I) in Mesp1, Isl1, and Mesp1/Isl1 Dox-inducible ESCs at D8 and D7 of differentiation, respectively, in the presence or absence of Dox from 
D2 to D4 or from D5 to D6. n = 4. Error bars indicate means ± SEM. TRE, tetracycline-responsive element.
 
Figure 8.  Model of the cellular hierarchy acting during cardio-
vascular  lineage  commitment.  During  ESC  differentiation, 
Mesp1-expressing  cells  represent  early  tripotent  cardiovas-
cular progenitors that are able to differentiate at the clonal 
level into CMs, ECs, and SMCs, representing early common 
progenitors for all cardiovascular lineages.JCB • VOLUME 192 • NUMBER 5 • 2011   764
Materials and methods
Reporter ESC line
A 5.6-kb genomic fragment upstream of the Mesp1 translation start 
(Haraguchi et al., 2001) was amplified by PCR, sequence verified, and 
subcloned upstream of the Venus-GFP sequence in a PL451 vector (Liu   
et al., 2003). The construct was linearized and electroporated in ESCs. Re-
sistant ES cell clones were selected with neomycin and screened for expres-
sion of the GFP during ESC differentiation. Bry-GFP ESC line generation 
and use were previously described elsewhere (provided by G. Keller,   
McEwen Center for Regenerative Medicine, Toronto, Ontario, Canada;   
Kattman et al., 2006).
Tetracycline-inducible ES cell lines
Isl1 ORF was amplified by PCR, sequence verified, and cloned in place of 
Mesp1–3×Flag  in  the  p2LoxMesp1–3×Flag-IRES-EGFP  vector  (Bondue   
et al., 2008). Combined expression of Mesp1 and Isl1 in A2lox cells was 
obtained by generating cell lines containing two tetracycline operators in 
tandem  in  the  p2Lox  backbone  (Kyba  et  al.,  2002),  introducing  the 
Mesp1–3×Flag sequence after the first tetracycline operator and the Isl1 
sequence after the second one. To generate the EN-Mesp1 construct, we 
performed a fusion protein between the first 298 amino acids of the repres-
sor domain of Drosophila EN and Mesp1 ORF. All these constructs were 
electroporated in A2Lox cells, and stable cell lines were selected as previ-
ously described (Bondue et al., 2008).
Flow cytometry
Staining for cTNT, BrdU, and active caspase-3 was performed as previ-
ously described (Bondue et al., 2008). Flk1 (VEGFR2) was stained using 
a  biotinylated  antibody  at  1:100  (clone  Avas12a1;  eBioscience)  re-
vealed by a streptavidin-phosphatidylethanolamine (PE)-Cy7 secondary 
antibody at 1:400 (BD). PDGFRa was stained using a PE- or an allophy-
cocyanin-coupled rat monoclonal antibody at 1:75 (clone APA5; eBiosci-
ence).  CXCR4  was  stained  using  an  A647-coupled  rat  monoclonal 
antibody  at  1:100  (clone  2B11;  eBioscience).  CD31  expression  was   
detected using a PE-coupled rat monoclonal antibody at 1:100 (clone 
MEC 13.3; BD). Living cells were gated by propidium iodide dye exclu-
sion. FACS analyses were performed on a FACSCanto or a FACSCalibur 
device (BD), and isolation of the cells was performed using a cell sorter 
(FACSAria; BD).
ESC culture and differentiation
ESCs were cultured on irradiated mouse embryonic fibroblasts in DME 
supplemented with 15% ESC-qualified FBS (Invitrogen), 0.1 mM nonessen-
tial amino acids (Invitrogen), 1 mM sodium-pyruvate (Invitrogen), 0.1 mM 
-mercaptoethanol  (Sigma-Aldrich),  100  U/ml  penicillin  (Invitrogen), 
100 µg/ml streptomycin (Invitrogen), and 1,000 U/ml leukemia inhibitory 
factor (ESGRO). ESC differentiation was performed in hanging drops of 
1,000 cells in 25 µl as previously described (Bondue et al., 2008). To as-
sess the cardiovascular potential of Mesp1-GFP and CXCR4/PDGFRa/Flk1 
TP cells, ESCs were cultured for 3 d in hanging drops in differentiation me-
dium consisting of the same medium without leukemia inhibitory factor but 
containing 15% of ESC-qualified serum (Invitrogen) and 0.5 mM ascorbic 
acid (Sigma-Aldrich; Bondue et al., 2008). At D3, dissociated cells were 
stained and sorted in HBSS containing 2% FBS, washed, and replated   
on gelatin-coated dishes in a serum-free medium based on StemPro-34   
(Invitrogen) supplemented with 100 U/ml penicillin, 100 µg/ml streptomy-
cin, 2 mM l-glutamine, 0.5 mM ascorbic acid (Sigma-Aldrich), 10 ng/ml 
basic FGF, 25 ng/ml FGF10, 5 ng/ml VEGF, 100 ng/ml PDGFRa, and 
150 ng/ml hDKK1 (Kattman et al., 2006). All growth factors were pur-
chased from R&D Systems. Medium was replaced on D5, D7, and D9 of 
differentiation. For low density culture assays, 50 isolated cells were re-
plated in each well of an 8-well Lab-Tek glass chamber slide (Thermo Fisher 
Scientific) with Y-27632 (EMD) at a final concentration of 10 µM for the 
first 48 h. Dox-inducible ESC lines were differentiated in DME containing 
15%  ESC-qualified  serum  and  0.5  mM  ascorbic  acid  (Sigma-Aldrich).   
After 4 d in hanging drops, ESCs were replated on gelatin-coated dishes 
for  further  differentiation.  Dox  (Sigma-Aldrich)  was  added  to  hanging 
drops at corresponding days to a final concentration of 1 µg/ml as previ-
ously described (Bondue et al., 2008).
Immunofluorescence analysis
Fixation, blocking, and primary and secondary antibodies as well as mounting 
medium used in this study were previously described (Bondue et al., 2008), 
except  for  the  anti-GFP  staining  (rabbit  polyclonal;  1:1,500;  Invitrogen). 
Counterstaining of nuclei was performed with Hoechst (1:2,000; Invitrogen). 
Immunostaining was acquired using a microscope (Axio Observer.Z1), 
a camera (AxioCam MR3 or MRc5), and the Axiovision software (Carl 
Zeiss,  Inc.).  Acquisitions  were  performed  at  room  temperature  using   
10 and 20× EC Plan Neofluar objectives (10× = 0.3 numerical aperture 
and 20× = 0.4 numerical aperture; Carl Zeiss, Inc.). Mosaics were gener-
ated by the Axiovision software using a 10% overlap between each single 
acquisition. Confocal pictures were acquired at room temperature using a 
multiphoton confocal microscope (LSM510 NLO; Carl Zeiss, Inc.) fitted on 
an inverted microscope (Axiovert M200; Carl Zeiss, Inc.) equipped with   
C-Apochromat (40× = 1.2 numerical aperture and 63× = 1.2 numerical ap-
erture) water immersion objectives (Carl Zeiss, Inc.). 0.35-mm-thick, 512 × 
512–pixel optical sections were collected sequentially for each fluorochrome. 
The datasets generated were merged and displayed with the LSM510 soft-
ware and exported in TIF image format.
Live-sample imaging
8 d after cell isolation at D3 and replating on gelatin-coated dishes, beating 
areas were imaged by time-lapse bright-field acquisitions using a micro-
scope (Axio Observer.Z1) and the Axiovision software. All acquisitions 
were performed at room temperature using a 10× EC Plan Neofluar objec-
tive (0.3 numerical aperture). Image sequences were compiled with the 
Axiovision software, and video files display 15 images/s.
RNA isolation, reverse transcription, quantitative PCR, and single-cell PCR
RNA extraction, DNase treatment, and RT-PCR were performed as previ-
ously described (Bondue et al., 2008). Quantitative PCR was performed 
using Brilliant II Fast SYBR qPCR Master Mix (Agilent Technologies) on a 
real-time PCR system (Mx3005P; Agilent Technologies). All primers were 
designed using Lasergene 7.2 software (DNAStar, Inc.) and are listed in 
Table S2. Single-cell PCR, generation of cDNA, and PCR amplification 
were performed as previously described (Jensen and Watt, 2006). In brief, 
after cDNA synthesis, two rounds of 35 cycles of amplifications were per-
formed by PCR, and the amplification product was used as a PCR template 
for  the  detection  of  gene  expression.  For  single-cell  PCR  experiments, 
CXCR4/PDGFRa/Flk1 TP cells were sorted directly in 96-well plates con-
taining the first strand buffer. The cDNA amplification procedure was used 
for the expression profiling of colonies obtained after differentiation of sin-
gle Mesp1-GFP cells sorted in 96 wells.
Microarray analysis
For microarray analysis, Mesp1-GFP cells were sorted at D3 directly in 
350 µl lysis buffer of the Absolutely microRNA kit (Agilent Technologies). 
RNA isolation and microarray analysis were performed in two biologically 
independent  replicates  as  previously  described  (Bondue  et  al.,  2008)   
using mouse genome 430 2.0 arrays (Affymetrix). To compare Mesp1-GFP 
and Mesp1 overexpression experiments, we plotted the distribution of the 
fold change of the probes that are significantly differentially expressed in 
the two experiments (fold change >1.5), representing a total of 1,425 
probes. Distributions were compared using 
2 test.
Online supplemental material
Fig.  S1  shows  the  differentiation  potential  of  Mesp1-GFP  and  Flk1/
PDGFRa/CXCR4 TP cells. Fig. S2 compares the fold change of probes   
affected in Mesp1 gain-of-function and Mesp1-GFP experiments. Fig. S3 shows 
the expression of Mesp1 in a subpopulation of Bry/Flk1-expressing cells.   
Fig. S4 characterizes inducible gene expression in Mesp1, Isl1, and Mesp1/Isl1   
ESCs. Video 1 shows beating areas in differentiated Mesp1-expressing   
cells.  Video  2  displays  beating  areas  in  differentiated  Mesp1-negative   
cells.  Video  3  shows  beating  areas  in  differentiated  all  sorted  cells. 
Table  S1  displays  the  functional  annotation  chart  of  Mesp1-enriched 
genes.  Table  S2  shows  primers  used  for  RT-PCR  and  single-cell  PCR. 
Online  supplemental  material  is  available  at  http://www.jcb.org/cgi/ 
content/full/jcb.201007063/DC1.
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